ArticleCancer cell international2026
G protein-coupled receptor 137B drives malignant progression and May serves as a diagnostic and prognostic biomarker in esophageal squamous cell carcinoma.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-Cell and Bulk Transcriptomics Identify GNGT1-High Malignant Epithelial Cells Associated With Immune Suppression in Esophageal Squamous Cell Carcinoma.Chemical biology & drug design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundG protein-coupled receptors (GPCRs) are widely involved in cell signal transduction, and their abnormal activation has been proved to be closely related to the occurrence and development of various cancers. However, the functions of a large number of members in the GPCR family have not been clarified. Among them, the orphan receptor GPR137B is particularly rare, and its role in tumors has been rarely studied systematically.
methodsThe expression of GPR137B in ESCC was confirmed using multi-database analysis and clinical tissue samples, and its prognostic value in ESCC was investigated. The role of GPR137B in ESCC was confirmed through in vivo and in vitro investigations. The probable mechanism of GPR137B in ESCC was investigated by GO and KEGG enrichment analysis and Western blotting. Bioinformatics analysis was employed to investigate the association of immune infiltration, while flow cytometry was utilised to validate the expression of PD-L1. Drug sensitivity analysis investigated the potential of GPR137B as a predictor of drug responsiveness.
resultsGPR137B had elevated levels in ESCC and was associated with unfavourable prognosis. GPR137B may enhance the proliferation, invasion, migration, and tumorigenesis of ESCC cells. GPR137B was associated with the non-classical Wnt/PCP signalling pathway in enrichment analyses. The suppression of GPR137B facilitated the epithelial-mesenchymal transition (EMT) by reducing the expression of Wnt5A, FZD6, and p-JNK, proteins associated with the non-classical Wnt/PCP signalling pathway. The expression of GPR137B was correlated with immune infiltration in ESCC, and flow cytometry indicated a relationship with PD-L1. GPR137B may serve as a prognostic and therapeutic target for ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.